NEW YORK, Dec. 15, 2015 /PRNewswire/ -- The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges. Plasma-derived therapeutics market
•The global human plasma-derived therapeutics market, worth $xxbillion in 2015, is set to grow at a CAGR of xx% to reach $xx billion by 2021.
•Rise in the global ageing population, increased awareness about the potential of plasma-derived therapeutics, early diagnosis of diseases, and the growing popularity of plasma-derived products in the emerging economies are the key factors driving the growth.
•However, there are significant challenges in handling the strict regulations of different countries with respect to selection of donors, plasma screening process, and fractionation process.
•In 2015, CSL Behring, Baxter, Grifols, Kedrion, and Octapharma were the top xx competitors; however, companies such as Sanquin are gaining ground quickly.
•In the past, there have been significant consolidations such as the $xx billion acquisition of Talecris in 2011 by Grifols. The market is further expected to witness big industry consolidations for economies of scale and market access.
•The IVIG segment will continue to be the market driver because of the heavy R&D investment in biologics development by market leaders such as Grifols, Octapharma, and CSL Behring.
•A recent pre-clinical research study at Stanford University showed that blood plasma derived from young mice and injected into older mice rejuvenated the health and memory of the older mice. Several other studies like this one may open up new indications such as Alzheimer's disease and other age-related diseases for the human plasma-derived therapeutics market in the coming years.
Methodology and Scope
•This research service focuses on human plasma-derived prescription drugs used for the treatment of liver and kidney diseases, burns, surgeries, cardiopulmonary bypass, hypovolemia, albumin deficiency (hypoalbuminemia), acute nephrosis, ovarian hyperstimulation syndrome, neonatal hyperbilirubinemia, acute respiratory distress syndrome (ARDS), hereditary angioedema, Von Willebrand disease (vWD), factor VII / X / XI / XIII deficiencies, haemophilia A and B, fibrinogen deficiency, hereditary anti-thrombin deficiency, surgical bleeding, chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP), rabies, tetanus, hepatitis A and B, chickenpox, primary immunodeficiency (PI), x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott–Aldrich syndrome.
•This study does not include recombinant products and bovine-plasma products. Only human plasma-derived products have been used in market segmentation, market size, and forecasting.
•A product and pipeline assessment is provided for marketed and investigational plasma-derived products. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources including disease organisation websites; public health organisation websites; company publications including annual reports, SEC filings, and press releases; government public sources; pipeline databases; and published articles in scientific journals.
Read the full report: http://www.reportlinker.com/p03471853-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001